

# Association of platelet-to-white blood cell ratio and platelet-to-neutrophil ratio with the risk of fatal stroke occurrence in older Chinese

**Zhi-bing Hu**

Guangzhou Twelfth People's Hospital

**Qiong-qiong Zhong**

Jinan University

**Ze-xiong Lu**

Sanya Central Hospital

**Feng Zhu** (✉ [chifengzhu@hotmail.com](mailto:chifengzhu@hotmail.com))

Guangzhou Twelfth People's Hospital

---

## Research Article

**Keywords:** white blood cell, platelet, neutrophil, stroke, ischaemic, haemorrhagic

**Posted Date:** March 9th, 2022

**DOI:** <https://doi.org/10.21203/rs.3.rs-1360183/v1>

**License:** © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License. [Read Full License](#)

---

## Abstract

## Background

White blood cell (WBC) and neutrophil (NEUT) counts, which are commonly inflammatory markers, have been related to an increased risk of fatal stroke. However, it is unclear whether platelet-to-white blood cell ratio (PWR) and platelet-to-neutrophil ratio (PNR) are related to the risk of fatal stroke in elderly populations.

## Methods

In total, 27811 participants without a stroke history at baseline were included and followed up for a mean of 14.3 years (standard deviation = 3.2), and 838 stroke deaths were recorded. The Cox proportional hazards regression was used to assess the relationships between the PWR and the PNR and the risk of fatal strokes.

## Results

Compared to the 1st quartile, an increased risk of fatal all stroke showed among the participants in the highest quartiles of both the WBC (adjusted hazard ratio (aHR) = 1.35, 95% confidence interval (CI) 1.09–1.66) and the NEUT (aHR = 1.45, 95% CI 1.18–1.79). The restricted cubic splines showed decreased trends in associations of the PWR and the PNR with the risk of fatal all stroke. A decreased risk of fatal all stroke showed in those with the highest quartiles for both the PWR (aHR = 0.73, 95% CI 0.53–1.00) and the PNR (aHR = 0.74, 95% CI 0.54–1.01). The participants with the 2nd, the 3rd and the 4th change quartiles for the PWR and the PNR had weak decreasing trends for the risk of fatal all stroke, compared to those in the 1st change quartile, and the significant associations were observed in those with an increase of 20% for the PWR with the risk of fatal haemorrhagic stroke (aHR = 0.47, 95% CI 0.22–0.95) and a decrease of 20% for the PNR with the risk of fatal all stroke (aHR = 1.33, 95% CI 0.99–1.79), compared to those with stable dynamic changes.

## Conclusions

Higher neutrophil count and platelet-to-neutrophil ratio were associated with a contrary risk of fatal stroke, with an increased for the former and a decreased for the later. A potentially chronic inflammation should be paid close attention to stroke occurrence in relatively healthy elderly populations.

## Background

Stroke, a major public health problem, has become a leading cause of deaths in China [1]. It is classified mainly as ischaemic and haemorrhagic stroke. A series of confounders such as hypertension, diabetes and smoking have been known as main risk factors in stroke [2–6], and were closely related to a chronic inflammation [7]. Atherosclerosis, an inflammatory disease [8, 9], plays an important role in stroke pathophysiology. The WBC acts positively in atherosclerotic thrombosis [10], and it has been related to an increased risk of fatal stroke [11, 12]; the NEUT releases its extracellular traps (NETs) and activates endothelial cells and the platelets (PLTs) in atherosclerotic plaque rupture or erosion [13, 14]. Additionally, the PLTs aggravated inflammation, promoted atherosclerosis [15], and led acute ischemic events involving thrombotic and hemorrhagic diseases [16, 17].

The platelet-to-white blood cell ratio (PWR) has been linked to an independently mortality risk in patients with acute exacerbation of chronic liver failure [18] or undergoing radical cystectomy [19], and it was related to a 90-day disability or death in acute ischemic stroke [20]. Similarly, the platelet-to-neutrophil ratio (PNR) was related to a hospitalization or a long-term mortality in the patients with infective endocarditis [21], and was an independent risk factor for ischemic stroke [22]. However, there are not studies so far in addressing the relationships between the PWR and the PNR and the risk of fatal stroke in a general community population. In this study, we based on the Guangzhou Biobank cohort study (GBCS) to investigate systematically the relationships between the PWR and the PNR and the risk of fatal stroke occurrence in a healthy elderly population.

## Methods

### Participants

All participants were recruited from a population of permanent residents aged 50 years or above in Guangzhou in southern China. Details of the GBCS have been reported previously [23]. The baseline (from September 1<sup>st</sup>, 2003 to February 28<sup>th</sup>, 2008) and follow up information included a face to face computer-assisted interview by trained nurses on lifestyle [24], the family and personal medical history and assessment of anthropometrics, blood pressure and laboratory tests. Each participant had been made an appointment in advance to ensure good health and was able to go to the designated place, and was able to sit and rest for at least half an hour before sampling and examination.

### Exposure indicators

Blood cell counts were performed with a cell counter (KX-21, Sysmex, Japan) in Guangzhou Twelfth People's Hospital [25]. The PWR and the PNR were calculated respectively from the PLT and the WBC, the PLT and the NEUT. Fasting glucose, cholesterol, triglycerides, liver and kidney function and high sensitivity C-reactive protein (hs-CRP) were measured by an analyzer (Cobas c-311, Roche, Switzerland). The laboratory performs internal and external quality control procedures according to the China Association of Laboratory Quality Control.

## Study outcomes

Information on underlying causes of death up to April 13<sup>th</sup> 2021 was obtained mostly via record linkage with the Guangzhou Centers for Disease Control and Prevention (GZCDC). Due to no other information for stroke severity, infarct volume, site of lesion and infectious complications as previous work [25], fatal stroke occurrence was chosen as only one outcome of this study. Death causes were coded according to the 10<sup>th</sup> revision of the International Classification of Diseases (ICD) as follows: I60~I69 for stroke; I60.0~I62.9 and I69.0~I69.2 for haemorrhagic stroke; I63.0~I63.9 and I69.3 for ischaemic stroke; and the other codes for unclassified stroke. The death certificates were verified by the GZCDC as part of their quality assurance programmed by cross-checking past medical history and conducting verbal autopsy by 5 senior clinicians from Guangzhou Twelfth People's Hospital, the Universities of Hong Kong, China and Birmingham, UK.

## Potential confounders

To examine the extent to which baseline factors in relation to the risks of all stroke, ischaemic stroke and haemorrhagic stroke, we included a series of factors in different models, according to our previous work [25]. Model 1 was a crude hazard ratio model without an adjustment for any confounders. Model 2 contained a multivariate adjustment for factors including sex, age, smoking (never, former and current), alcohol consumption (never, former and current), International Physical Activity Questionnaire-assessed physical activity (inactive, moderate and active) body mass index (BMI, defined as weight in kg ÷ eight in m<sup>2</sup>), self-rated health, hypertension, diabetes, dyslipidaemia, cancer, genitourinary disease, chest disease and the platelet count. Model 3 included hs-CRP as a competing confounder in addition to confounders in model 2.

## Statistical analysis

A series of variables, including the WBC, the NEUT, the PLT, the PWR and the PNR, were respectively classified by quartiles: the 1<sup>st</sup> quartile (<5.3\*10<sup>9</sup>/L), the 2<sup>nd</sup> quartile (5.3–6.1\*10<sup>9</sup>/L), the 3<sup>rd</sup> quartile (6.2–7.2\*10<sup>9</sup>/L) and the 4<sup>th</sup> quartile (>7.2\*10<sup>9</sup>/L) for the WBCs; the 1<sup>st</sup> quartile (<3.0\*10<sup>9</sup>/L), the 2<sup>nd</sup> quartile (3.0–3.6\*10<sup>9</sup>/L), the 3<sup>rd</sup> quartile (3.7–4.4\*10<sup>9</sup>/L) and the 4<sup>th</sup> quartile (>4.5\*10<sup>9</sup>/L) for the NEUTs; the 1<sup>st</sup> quartile (<190\*10<sup>9</sup>/L), the 2<sup>nd</sup> quartile (191–223\*10<sup>9</sup>/L), the 3<sup>rd</sup> quartile (224–260\*10<sup>9</sup>/L) and the 4<sup>th</sup> quartile (>260\*10<sup>9</sup>/L) for the PLTs; the 1<sup>st</sup> quartile (≤30), the 2<sup>nd</sup> quartile (30.01–36.11), the 3<sup>rd</sup> quartile (36.12–43.38) and the 4<sup>th</sup> quartile (≥43.39) for the PWRs; the 1<sup>st</sup> quartile (≤48.64), the 2<sup>nd</sup> quartile (48.65–61.11), the 3<sup>rd</sup> quartile (61.12–76.25) and the 4<sup>th</sup> quartile (≥76.25) for the PNRs; the PWR and the PNR were assessed as continuous parameters using a restricted cubic spline curve model (RCS) with 3 knots at the 10<sup>th</sup>, the 50<sup>th</sup>, and the 90<sup>th</sup> percentiles. Continuous variables were described by the mean ± standard deviation, and categorical variables were described by frequency and percentage. The chi-square test and Fisher's exact test were used for categorical variables, and analysis of variance (ANOVA) and the Kruskal-Wallis test were used for continuous variables. Sensitivity analyses were conducted in which model 2 and model 3 was repeated with a further adjustment for hs-CRP. All analyses were performed using STATA (Version 14.0; StataCorp LP, College Station, TX, USA). All *p* values were 2 sided, and statistical significance was defined as *p*< 0.05; *p* values for trends in models were calculated as ordinal scores from the 2<sup>nd</sup>, the 3<sup>rd</sup> and the 4<sup>th</sup> quartiles when taking the 1<sup>st</sup> as reference. All methods were performed in accordance with the Declaration of Helsinki.

## Results

### Baseline characteristics

In total, 30,430 participants were screened, and 2,634 participant were excluded, including 286 because of a previous history of stroke, 315 because of an unclear stroke history, 372 because of loss to follow-up with unknown vital status, and 1,661 because of incomplete information on the WBC, the NEUT, the LYM and platelet counts, hypertension, diabetes, dyslipidaemia, smoking, alcohol consumption, physical activity, BMI, self-rated health, cancer, genitourinary disease or chest disease. Eventually a total of 27,796 participants at baseline were included, and 838 stroke deaths (413 ischaemic, 264 haemorrhagic and 161 unclassified) were recorded after a mean follow-up time of 14.3 (standard deviation=3.2) years with 399,116 person-years in this study (Figure 1).

The baseline characteristics are presented in Table 1. Compared to those in the 1<sup>st</sup> quartile, the participants in the highest PWR and the PNR included more women, were younger, and had more dyslipidaemia, active physical activity, genitourinary disease. These subjects were less likely to have BMI ≥ 28 kg/m<sup>2</sup>, had lower hypertensive, and had less current smoking and alcohol drinking, and chest disease and diabetes.

### The WBC, the NEUT and the PLT in relation to the risk of fatal stroke

We observed firstly that the participants in the highest WBC quartile had an increased risk of fatal all stroke (aHR=1.35, 95% CI 1.09-1.66, *P*=0.005), compared to those in the 1<sup>st</sup> WBC quartile; and those in the 2<sup>nd</sup>, the 3<sup>rd</sup> and the 4<sup>th</sup> WBC quartiles had an increased risk trend in fatal all stroke (*P*<0.001) and fatal ischaemic stroke (*P*=0.002), respectively; The NEUTs had similar results for fatal all stroke (aHR=1.45, 95% CI 1.18-1.79, *P*<0.001) and fatal ischaemic stroke (aHR=1.58, 95% CI 1.17-2.12, *P*=0.03), respectively. However, no other significant relationships were observed between the PLT and the risk of fatal strokes besides an increased risk for fatal unclassified stroke (aHR=1.72, 95% CI 1.11-2.65, *P*=0.01) (Table 2, Figure3).

### The PWR and the PNR in relation to the risk of fatal stroke in the RCS model

The RCS showed linear relationships between the PWR and the PNR and the risk of fatal all stroke after adjustments for potential confounders. Higher levels of the PWR and the PNR were associated with a decreased risk of fatal all stroke, and the cutoff values were 35 for the PWR and 74 for the PNR (Figure 2).

### The PWR in relation to the risk of fatal stroke

After adjustment for a series of factors and compared to those in the 1<sup>st</sup> quartile, no significant associations of the PWR with the risks of fatal strokes were observed, although very weak decreasing trends for risks of fatal all stroke and fatal ischemic stroke were found among the participants in the 2<sup>nd</sup>, the 3<sup>rd</sup> and the 4<sup>th</sup> PNR quartiles (the left side of Table 3 and Figure 4A). Such trends were strengthened, and the highest PWR quartile was related to a decreased risk of fatal ischemic stroke (aHR=0.73, 95% CI 0.53-1.00,  $P=0.05$ ) among those without a history of relative cardiovascular diseases (CVD) at baseline and further adjustment for hs-CRP (the left side of Table 4 and Figure 5A).

### The PNR in relation to the risk of fatal stroke

After adjustment for a series of factors and compared to those in the 1<sup>st</sup> quartile, the participants in the 4<sup>th</sup> PNR quartile were related to a decreased risk of fatal all stroke (aHR=0.76, 95% CI 0.61-0.94,  $P=0.03$ ) and fatal ischemic stroke (aHR=0.74, 95% CI 0.55-1.01,  $P=0.06$ ), respectively; the participants in the 2<sup>nd</sup>, the 3<sup>rd</sup> and the 4<sup>th</sup> PNR quartiles had a weak decreasing trends for risks of fatal all stroke ( $P=0.03$ ) and fatal ischemic stroke ( $P=0.06$ ) (the right side of Table 3 and Figure 4 B). However, such trends were weakened, and no significant associations were found among those without CVD at baseline and further adjustment for hs-CRP, besides a weak decreased risk of fatal all stroke (aHR=0.74, 95% CI 0.54-1.01) in those with the highest PNR quartile (the right side of Table 4 and Figure 5 B).

### The PWR and PNR changes in relation to the risk of fatal stroke

The basic characteristics of the participants at the 1<sup>st</sup> follow-up are shown in Supplementary table 1. Compared to those with a stable PWR (from -20% to 20%), the participants with a PWR gain (>20%) had higher proportions of former and current smokers, BMIs from 18.5 to 23.9 kg/m<sup>2</sup> and higher PLT counts; lower proportions of dyslipidaemia; and lower WBC and NEUT counts (all  $P<0.05$ ).

For dynamic changes, the participants in the 2<sup>nd</sup>, the 3<sup>rd</sup> and the 4<sup>th</sup> change quartiles of the PWR and the PNR had weak decreasing trends for the risk of fatal all stroke, compared to the participants in the 1<sup>st</sup> quartile, and significant associations of fatal all stroke risks were observed in those with the highest quartiles for the PWR (aHR=0.71, 95% CI 0.58-0.93,  $P=0.03$ ) and the PNR (aHR=0.73, 95% CI 0.54-1.01,  $P=0.05$ ) (Table 5 and Figure 6). The participants with an increase of 20% for the PWR but a decrease of 20% for the PNR shared respectively the risk of fatal haemorrhagic stroke (aHR=0.47, 95% CI 0.22-0.95,  $P=0.03$ ) and the risk of fatal all stroke (aHR=1.33, 95% CI 0.99-1.79,  $P=0.05$ ), compared to the participants with stable levels of their dynamic changes at -20%~20% (Figure 7 and Supplementary Table 2).

## Discussion

We are the first addressing the PWR and the PNR in relation to the risk of fatal stroke occurrence in elderly populations. In this study, we showed that higher level of the PNR but not the PWR was associated with a decreased risk of fatal all stroke, although the NEUT and the WBC showed a reversed association; and these associations are independent of a series of factors including age, sex, education, occupation, hypertension, diabetes, dyslipidaemia, smoking habit, alcohol consumption, physical activity, BMI, self-rated health, cancer, genitourinary disease, chest disease, platelets and hs-CRP.

In ischemic stroke, the clots were generated to block cerebral arteries including atherosclerosis of great arteries, cardiogenic embolism and small artery occlusion [26] in which atherosclerosis had accompanied with a chronic vascular inflammation or endothelial dysfunction [27]. Lymphocytes and NEUTs took part in the pathogenesis of atherosclerosis [9], and promoted thrombosis formation in stroke and a cardiogenic thromboembolic stroke [28]. In the other hand, the PLTs interacted with a host of leukocytes in thrombocytopenic tissue haemorrhage [29], and the PLT hemITAM signaling took part in vascular barrier integrity [30–33]. Thus, the interaction between LTs and the NEUTs are closely related to stroke in which a chronic inflammation has been in chaperonage.

The WBC and the NEUT have been linked to the risk of stroke events [11, 12, 34–36], and the PLT was closely linked to mortality risks of thrombotic and hemorrhage diseases [16]. We tried firstly to explore the associations of fatal stroke occurrence with the PWR and the PNR who are respectively combined by the PLT and the WBC and the NEUT, and corresponding results should mainly reflect the roles of the WBC and the NEUT again in fatal strokes [25] because we observed significant associations of the WBC and the NEUT but not the PLT with the risks of fatal strokes in relatively healthy elderly populations. In this study, all of the WBC, the NEUT, and the PNR were related to the risk of fatal stroke occurrence, regardless of a restricted cubic spline model or a quartile model in our study; The PWR and the PNR presented respectively different associations with fatal haemorrhagic and fatal ischaemic stroke, although they had similar associations with fatal ischaemic stroke, but the associations are reversed to those with the WBC and the NEUT. Such results suggest an equal linkage of stroke occurrence to a pre-existing chronic low-grade systemic inflammation in a large cities' elderly population. The reasons are that we conducted a further hs-CRP adjustment to exclude acute inflammations, and we used a series of data from relatively healthy elders who had been made an appointment in advance to ensure good health and were able to come the designated place, and the WBC and the NEUT are taken as the denominators in ratios of the PWR and the PNR.

We conducted a large, prospective design for a study of the general Southern Chinese population, and the acquired information allows for systemic adjustments for additional potential confounders in this study because a physical examination and a questionnaire involving a total of 800 questions were completed for all participants. Nevertheless there are limitations in this study. First, we obtained only the death information via record linkage with the GZCDC, and corresponding results, with death as the only outcome, are obviously weakened due to the lack of other outcomes of stroke events. Second, the inaccurate risk factors such as self-rated health may take influences on our results due to a linkage to the objective indicators predicting health status, in addition to a series of potential confounders. Third, the subjects of this study could not represent Chinese individuals due to a limitation of the general populations in South China. Fourth, the unclassified strokes of this study limited the strength to address fatal strokes, especially ischaemic stroke and haemorrhagic stroke.

## Conclusions

Our findings indicated that higher neutrophil count and platelet-to-neutrophil ratio were associated with contrary risks of fatal stroke occurrence, with an increased for the former and a decreased for the later. An asymptomatic chronic low-grade systemic inflammation should therefore play a key role in stroke among relatively healthy elderly populations.

## Abbreviations

WBC  
white blood cell  
NEUT  
neutrophil  
PLT  
platelet  
PWR  
platelet-to-white blood cell ratio  
PNR  
platelet-to-neutrophil ratio  
hs-CRP  
high sensitivity C-reactive protein  
ICD  
International Classification of Diseases  
aHR  
adjusted hazard ratio  
CI  
confidence interval  
CVD  
cardiovascular diseases  
GBCS  
Guangzhou Biobank Cohort Study  
GZCDC  
Guangzhou Centers for Disease Control and Prevention.

## Declarations

### Ethics approval and consent to participate

The study was approved by the Guangzhou Medical Ethics Committee of the Chinese Medical Association. Informed consent was obtained from all the participants and from the guardians of death participants before participation. All methods in this study were performed in accordance with the Declaration of Helsinki.

### Consent for publication

Not applicable.

### Availability of data and materials

The datasets used during the current study are available from the corresponding author on reasonable request.

### Competing interests

The authors declare that they have no competing interests.

### Funding

This work was supported by the Guangzhou Science and Technology Program (201704030132, 202102080467). The funders had no role in design, data or analysis, or preparation of the manuscript.

### Authors' contributions

ZBH and ZQQ contributed equally to this paper for data collection and analysis. ZXL contributed partly to this paper for data collection and analysis. FZ contributed to the study design and wrote the manuscript. All authors reviewed the manuscript.

### Acknowledgements

The Guangzhou Biobank Cohort Study investigators included Guangzhou Twelfth People's Hospital, namely, Weisen Zhang, Min Cao, Tong Zhu, Bin Liu, and Caoqiang Jiang (Co-PI); the University of Hong Kong, namely, C.M. Schooling, S.M. McGhee, G.M. Leung, R. Fielding, and Taihing Lam (Co-PI); and the

## References

1. Zhou M, Wang H, Zhu J, Chen W, Wang L, Liu S, Li Y, Wang L, Liu Y, Yin P *et al*: **Cause-specific mortality for 240 causes in China during 1990-2013: a systematic subnational analysis for the Global Burden of Disease Study 2013**. *Lancet* 2016, **387**(10015):251-272.
2. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R, Prospective Studies C: **Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies**. *Lancet* 2002, **360**(9349):1903-1913.
3. Bragg F, Holmes MV, Iona A, Guo Y, Du H, Chen Y, Bian Z, Yang L, Herrington W, Bennett D *et al*: **Association Between Diabetes and Cause-Specific Mortality in Rural and Urban Areas of China**. *Jama* 2017, **317**(3):280-289.
4. Koton S, Schneider AL, Rosamond WD, Shahar E, Sang Y, Gottesman RF, Coresh J: **Stroke incidence and mortality trends in US communities, 1987 to 2011**. *Jama* 2014, **312**(3):259-268.
5. Chen Z, Peto R, Zhou M, Iona A, Smith M, Yang L, Guo Y, Chen Y, Bian Z, Lancaster G *et al*: **Contrasting male and female trends in tobacco-attributed mortality in China: evidence from successive nationwide prospective cohort studies**. *Lancet* 2015, **386**(10002):1447-1456.
6. Thun MJ, Apicella LF, Henley SJ: **Smoking vs other risk factors as the cause of smoking-attributable deaths: confounding in the courtroom**. *Jama* 2000, **284**(6):706-712.
7. Portegies ML, Bos MJ, Hofman A, Heeringa J, Franco OH, Koudstaal PJ, Ikram MA: **Role of Prestroke Vascular Pathology in Long-Term Prognosis After Stroke: The Rotterdam Study**. *Stroke* 2016, **47**(1):80-87.
8. Vaccarezza M, Balla C, Rizzo P: **Atherosclerosis as an inflammatory disease: Doubts? No more**. *International journal of cardiology Heart & vasculature* 2018, **19**:1-2.
9. Ross R: **Atherosclerosis—an inflammatory disease**. *The New England journal of medicine* 1999, **340**(2):115-126.
10. Libby P, Ridker PM, Hansson GK: **Progress and challenges in translating the biology of atherosclerosis**. *Nature* 2011, **473**(7347):317-325.
11. Brown DW, Ford ES, Giles WH, Croft JB, Balluz LS, Mokdad AH: **Associations between white blood cell count and risk for cerebrovascular disease mortality: NHANES II Mortality Study, 1976-1992**. *Annals of epidemiology* 2004, **14**(6):425-430.
12. Jee SH, Park JY, Kim HS, Lee TY, Samet JM: **White blood cell count and risk for all-cause, cardiovascular, and cancer mortality in a cohort of Koreans**. *American journal of epidemiology* 2005, **162**(11):1062-1069.
13. Doring Y, Soehnlein O, Weber C: **Neutrophil Extracellular Traps in Atherosclerosis and Atherothrombosis**. *Circulation research* 2017, **120**(4):736-743.
14. Quillard T, Franck G, Mawson T, Folco E, Libby P: **Mechanisms of erosion of atherosclerotic plaques**. *Current opinion in lipidology* 2017, **28**(5):434-441.
15. Fuentes QE, Fuentes QF, Andres V, Pello OM, Font de Mora J, Palomo GI: **Role of platelets as mediators that link inflammation and thrombosis in atherosclerosis**. *Platelets* 2013, **24**(4):255-262.
16. Tsai MT, Chen YT, Lin CH, Huang TP, Tarng DC, Taiwan Geriatric Kidney Disease Research G: **U-shaped mortality curve associated with platelet count among older people: a community-based cohort study**. *Blood* 2015, **126**(13):1633-1635.
17. Fang HY, Lin CY, Ko WJ: **Hematology and coagulation parameters predict outcome in Taiwanese patients with spontaneous intracerebral hemorrhage**. *European journal of neurology* 2005, **12**(3):226-232.
18. Jie Y, Gong J, Xiao C, Zhu S, Zhou W, Luo J, Chong Y, Hu B: **Low Platelet to White Blood Cell Ratio Indicates Poor Prognosis for Acute-On-Chronic Liver Failure**. *BioMed research international* 2018, **2018**:7394904.
19. Schulz GB, Grimm T, Buchner A, Jokisch F, Grabbert M, Schneevogt BS, Kretschmer A, Stief CG, Karl A: **Prognostic Value of the Preoperative Platelet-to-leukocyte Ratio for Oncologic Outcomes in Patients Undergoing Radical Cystectomy for Bladder Cancer**. *Clinical genitourinary cancer* 2017, **15**(6):e915-e921.
20. Chen Z, Huang Y, Li S, Lin J, Liu W, Ding Z, Li X, Chen Y, Pang W, Yang D *et al*: **Platelet-to-White Blood Cell Ratio: A Prognostic Predictor for 90-Day Outcomes in Ischemic Stroke Patients with Intravenous Thrombolysis**. *Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association* 2016, **25**(10):2430-2438.
21. Wei XB, Liu YH, He PC, Yu DQ, Tan N, Zhou YL, Chen JY: **The impact of admission neutrophil-to-platelet ratio on in-hospital and long-term mortality in patients with infective endocarditis**. *Clinical chemistry and laboratory medicine* 2017, **55**(6):899-906.
22. Long H, Qin K, Chen J, Chen Y, Chen L, Zeng J, Liang Z: **Biomarkers of gastric cancer-related ischemic stroke and its underlying pathogenesis**. *Medicine* 2018, **97**(17):e0493.
23. Jiang C, Thomas GN, Lam TH, Schooling CM, Zhang W, Lao X, Adab P, Liu B, Leung GM, Cheng KK: **Cohort profile: The Guangzhou Biobank Cohort Study, a Guangzhou-Hong Kong-Birmingham collaboration**. *International journal of epidemiology* 2006, **35**(4):844-852.
24. Deng HB, Macfarlane DJ, Thomas GN, Lao XQ, Jiang CQ, Cheng KK, Lam TH: **Reliability and validity of the IPAQ-Chinese: the Guangzhou Biobank Cohort study**. *Medicine and science in sports and exercise* 2008, **40**(2):303-307.
25. Hu ZB, Lu ZX, Zhu F, Jiang CQ, Zhang WS, Pan J, Jin YL, Xu L, Thomas GN, Cheng K *et al*: **Higher total white blood cell and neutrophil counts are associated with an increased risk of fatal stroke occurrence: the Guangzhou biobank cohort study**. *BMC Neurol* 2021, **21**(1):470.
26. Adams HP, Jr., Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, Marsh EE, 3rd: **Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment**. *Stroke* 1993, **24**(1):35-41.
27. Gistera A, Hansson GK: **The immunology of atherosclerosis**. *Nature reviews Nephrology* 2017, **13**(6):368-380.

28. Laridan E, Denorme F, Desender L, Francois O, Andersson T, Deckmyn H, Vanhoorelbeke K, De Meyer SF: **Neutrophil extracellular traps in ischemic stroke thrombi.** *Annals of neurology* 2017, **82**(2):223-232.
29. Hillgruber C, Poppelmann B, Weishaupt C, Steingraber AK, Wessel F, Berdel WE, Gessner JE, Ho-Tin-Noe B, Vestweber D, Goerge T: **Blocking neutrophil diapedesis prevents hemorrhage during thrombocytopenia.** *The Journal of experimental medicine* 2015, **212**(8):1255-1266.
30. Rahman M, Zhang S, Chew M, Ersson A, Jeppsson B, Thorlacius H: **Platelet-derived CD40L (CD154) mediates neutrophil upregulation of Mac-1 and recruitment in septic lung injury.** *Annals of surgery* 2009, **250**(5):783-790.
31. Duerschmied D, Suidan GL, Demers M, Herr N, Carbo C, Brill A, Cifuni SM, Mauler M, Cicko S, Bader M *et al.*: **Platelet serotonin promotes the recruitment of neutrophils to sites of acute inflammation in mice.** *Blood* 2013, **121**(6):1008-1015.
32. Perazzio SF, Soeiro-Pereira PV, Dos Santos VC, de Brito MV, Salu B, Oliva MLV, Stevens AM, de Souza AWS, Ochs HD, Torgerson TR *et al.*: **Soluble CD40L is associated with increased oxidative burst and neutrophil extracellular trap release in Behcet's disease.** *Arthritis research & therapy* 2017, **19**(1):235.
33. Yokoyama S, Ikeda H, Haramaki N, Yasukawa H, Murohara T, Imaizumi T: **Platelet P-selectin plays an important role in arterial thrombogenesis by forming large stable platelet-leukocyte aggregates.** *Journal of the American College of Cardiology* 2005, **45**(8):1280-1286.
34. Qu X, Shi J, Cao Y, Zhang M, Xu J: **Prognostic Value of White Blood Cell Counts and C-reactive Protein in Acute Ischemic Stroke Patients After Intravenous Thrombolysis.** *Current neurovascular research* 2018, **15**(1):10-17.
35. Fang YN, Tong MS, Sung PH, Chen YL, Chen CH, Tsai NW, Huang CJ, Chang YT, Chen SF, Chang WN *et al.*: **Higher neutrophil counts and neutrophil-to-lymphocyte ratio predict prognostic outcomes in patients after non-atrial fibrillation-caused ischemic stroke.** *Biomed J* 2017, **40**(3):154-162.
36. Furlan JC, Vergouwen MD, Fang J, Silver FL: **White blood cell count is an independent predictor of outcomes after acute ischaemic stroke.** *European journal of neurology* 2014, **21**(2):215-222.

## Tables

**Table 1** Baseline characteristics by the PWR and the PNR quartiles of participants in the GBCS (n=27,796)

Characteristic	Quartiles of the PWR				P	Quartiles of the PNR				P
	the 1 <sup>st</sup> (≤ 30)	the 2 <sup>nd</sup> (30.01– 36.11)	the 3 <sup>rd</sup> (36.12– 43.38)	the 4 <sup>th</sup> (≥43.39)		the 1 <sup>st</sup> (≤ 48.64)	the 2 <sup>nd</sup> (48.65– 61.11)	the 3 <sup>rd</sup> (61.12– 76.25)	the 4 <sup>th</sup> (≥76.25)	
Number, n	7020	6872	6955	6949		6948	6843	6959	6946	
Age (years)	63.6±7.0	62.5±7.0	61.6±7.0	60.3±6.8	< 0.001	63.8±7.1	62.6±7.1	61.5±7.0	60.1±6.7	< 0.001
Sex, male (%)	3060(43.6)	2029(29.5)	1516(21.8)	1021(14.7)	< 0.001	3036(43.7)	2110(30.4)	1466(21.1)	1014(14.6)	< 0.001
Hypertension, n (%)	2257(32.2)	2039(29.7)	1908(27.4)	1609(23.2)	< 0.001	2298(33.1)	2037(29.3)	1932(27.8)	1546(22.3)	< 0.001
Diabetes, n (%)	1290(18.4)	930(13.5)	844(12.1)	564(8.1)	< 0.001	1280(18.4)	958(13.8)	822(11.8)	568(8.2)	< 0.001
Dyslipidaemia, n (%)	5571(79.4)	5751(83.7)	5837(83.9)	5853(84.2)	< 0.001	5485(78.9)	5760(83.0)	5871(84.4)	5896(84.9)	< 0.001
Smoking, n (%)					< 0.001					< 0.001
never	4857(69.2)	5500(80.0)	5913(85.0)	6244(89.8)		4780(68.8)	5543(79.8)	5946(85.4)	6245(89.9)	
ever	916(13.0)	664(9.7)	558(8.0)	381(5.5)		942(13.6)	688(9.9)	520(7.5)	369(5.3)	
current	1247(17.8)	708(10.3)	484(7.0)	324(4.7)		1226(17.6)	712(10.3)	493(7.1)	332(4.8)	
Alcohol drinking, n (%)					< 0.001					< 0.001
never	4772(68.0)	4836(70.4)	4965(71.4)	4955(71.3)		4760(68.5)	4828(69.5)	4939(71.0)	5001(72.0)	
ever	206(2.9)	168(2.4)	142(2.0)	124(1.8)		225(3.2)	156(2.2)	127(1.8)	132(1.9)	
current	2042(29.1)	1868(27.2)	1848(26.6)	1870(26.9)		1963(28.3)	1959(28.3)	1893(27.2)	1813(26.1)	
Body mass index, kg/m <sup>2</sup>					< 0.001					< 0.001
<18.5	266(3.8)	288(4.2)	302(4.3)	390(5.6)		285(4.1)	308(4.4)	298(4.3)	355(5.1)	
18.5 – 23.9	3258(46.4)	3290(47.9)	3532(50.8)	3859(55.6)		3320(47.8)	3272(47.1)	3480(50.0)	3867(55.7)	
24 – 27.9	2643(37.6)	2531(36.8)	2466(35.5)	2212(31.8)		2521(36.3)	2604(37.5)	2508(36.0)	2219(31.9)	
≥28	853(12.2)	763(11.1)	655(9.4)	488(7.0)		822(11.8)	759(10.9)	673(9.7)	505(7.3)	
Physical activity, n (%)					< 0.001					< 0.001
inactive	555(7.9)	523(7.6)	560(8.1)	617(8.9)		547(7.9)	522(7.5)	546(7.8)	640(9.2)	
moderate	2965(42.2)	2873(41.8)	2813(40.4)	2685(38.6)		2965(42.7)	2939(42.3)	2789(40.1)	2643(38.1)	
active	3500(49.9)	3476(50.6)	3582(51.5)	3647(52.5)		3436(49.5)	3482(50.2)	3624(52.1)	3663(52.7)	
Self-rated health, n (%) (good/very good)	5751(81.9)	5670(83.0)	5795(83.3)	5714(82.2)	0.097	5651(81.3)	5798(83.5)	5753(82.7)	5764(83.0)	0.006
Cancer, n (%)	123(1.8)	123(1.8)	157(2.3)	136(2.0)	0.12	109(1.6)	133(1.9)	151(2.2)	146(2.1)	0.04
GD, n (%)	1735(24.7)	1770(25.8)	1915(27.5)	1982(28.5)	< 0.001	1702(24.5)	1832(26.4)	1882(27.0)	1986(28.6)	< 0.001
Chest disease, n (%)	1155(16.5)	1017(14.8)	1011(14.5)	1030(14.8)	0.006	1123(16.2)	1027(14.8)	1027(14.8)	1036(14.9)	0.06
WBC, *10 <sup>9</sup> /L	7.5±1.7	6.6±1.3	6.0±1.6	5.3±1.1	< 0.001	7.6±1.7	6.6±1.2	6.0±1.2	5.2±1.0	< 0.001
NEUT, *10 <sup>9</sup> /L	4.7±1.5	4.0±1.3	3.6±1.1	3.0±0.9	< 0.001	5.0±1.4	4.0± 0.9	3.5±0.8	2.8±0.7	< 0.001
PLT, *10 <sup>9</sup> /L	185.8±46.3	218.2±42.9	237.5±46.0	268.0±61.0	< 0.001	193.7±50.7	220.8±48.1	236.2±51.1	258.3±60.7	< 0.001
hs-CRP, mg/L	3.8±3.1	3.5±2.8	3.4±2.8	3.3±2.6	< 0.001	4.1±3.2	3.5±2.7	3.4±2.7	3.1±2.6	< 0.001
All stroke	295 (4.2)	215 (3.1)	188 (2.7)	140 (2.0)	<	315 (4.5)	210 (3.0)	186 (2.7)	127 (1.8)	<

					0.001					0.001
Ischaemic stroke	146 (2.1)	116 (1.7)	88 (1.3)	63 (0.9)	< 0.001	167 (2.5)	102 (1.5)	83 (1.2)	61 (0.9)	< 0.001
Haemorrhagic stroke	99 (1.5)	58 (0.9)	62 (0.9)	45 (0.7)	< 0.001	95 (1.4)	62 (0.9)	66 (1.0)	41 (0.6)	< 0.001
Unclassified stroke	50 (0.7)	41 (0.6)	38 (0.6)	32 (0.5)	0.22	53 (0.8)	46 (0.7)	37 (0.5)	25 (0.4)	0.009

Hypertension: systolic blood pressure,  $\geq 140$  mmHg, or diastolic blood pressure,  $\leq 90$  mmHg, medication and diagnosis; diabetes: fasting blood glucose  $\geq 7$  mmol/L, medication or diagnosis; dyslipidaemia: total cholesterol  $\geq 5.2$  mmol/L, triglyceride  $\geq 1.7$  mmol/L, low density lipoprotein  $\geq 3.4$  mmol/L, high density lipoprotein  $< 1.0$  mmol/L, medication and diagnosis; WBC: white blood cell count; hs-CRP: high sensitivity C-reactive protein; NEUT: neutrophil; Platelet: PLT; PWR: platelet to white blood cell ratio; PNR: platelet to neutrophil ratio; GD: Genitourinary disease (including nephropathy, prostatic disease, and gynecologic diseases); chest disease: including COPD, chronic bronchitis, emphysema, asthma, tuberculosis, and pneumonia.

**Table 2** Association of the WBC, the NEUT and the PLT with the risk of fatal stroke in the GBCS, 2003-2021 (n=27,796)

	Quartiles of the WBC (*10 <sup>9</sup> /L)				P value trend	Quartiles of the NEUT (*10 <sup>9</sup> /L)				P value trend	Quartiles of the PLT (*	
	the 1 <sup>st</sup> (<5.3)	the 2 <sup>nd</sup> (5.3-6.1)	the 3 <sup>rd</sup> (6.2-7.2)	the 4 <sup>th</sup> (>7.2)		the 1 <sup>st</sup> (<3.0)	the 2 <sup>nd</sup> (3.0-3.6)	the 3 <sup>rd</sup> (3.7-4.4)	the 4 <sup>th</sup> (>4.5)		the 1 <sup>st</sup> (<190)	the 2 <sup>nd</sup> (191-223)
<b>All stroke</b>												
Person years	100,332	111,351	91,360	96,072		106,915	89,125	108,359	94,718		100,941	99,855
per 10 <sup>5</sup> person-years	164.4	167.9	211.2	304.9		143.1	186.2	200.3	318.8		244.7	189.3
No. of deaths	165	187	193	293		153	166	217	302		247	189
Model 1 (HR; 95% CI)	Ref.	1.01 (0.82-1.25)	1.28 (1.04-1.58) <sup>a</sup>	1.86 (1.54-2.26) <sup>c</sup>	< 0.001	Ref.	1.30 (1.04-1.62) <sup>a</sup>	1.40 (1.13-1.72) <sup>b</sup>	2.24 (1.85-2.73) <sup>c</sup>	< 0.001	Ref.	0.77(0.64-0.93) <sup>b</sup>
Pvalue		0.89	0.02	< 0.001			0.02	0.002	< 0.001			0.007
Model 2 (HR; 95% CI)	Ref.	0.89 (0.72-1.10)	1.04 (0.84-1.29)	1.35 (1.09-1.66) <sup>b</sup>	< 0.001	Ref.	1.09 (0.88-1.37)	1.08 (0.87-1.34)	1.45 (1.18-1.79) <sup>c</sup>	0.001	Ref.	0.93 (0.77-1.13)
Pvalue		0.28	0.71	0.005			0.80	0.68	<0.001			0.45
<b>Ischaemic stroke</b>												
Person years	99,489	110,242	90,482	94,691		106,105	88,296	107,110	93,394		99,742	98,839
per 10 <sup>5</sup> person-years	84.4	72.6	110.5	157.3		67.8	95.1	88.7	173.4		123.1	91.0
No. of deaths	84	80	100	149		72	84	95	162		123	90
Model 1 (HR; 95% CI)	Ref.	0.85 (0.63-1.16)	1.30 (0.97-1.74)	1.87 (1.43-2.44) <sup>c</sup>	< 0.001	Ref.	1.40 (1.02-1.92) <sup>a</sup>	1.30 (0.96-1.77)	2.57 (1.95-3.39) <sup>c</sup>	< 0.001	Ref.	0.73 (0.56-0.96) <sup>a</sup>
Pvalue		0.30	0.07	< 0.001			0.03	0.09	< 0.001			0.03
Model 2 (HR; 95% CI)	Ref.	0.73 (0.53-0.99) <sup>a</sup>	1.02 (0.75-1.37)	1.28 (0.96-1.71)	0.002	Ref.	1.15 (0.83-1.58)	0.97 (0.71-1.33)	1.58 (1.17-2.12) <sup>a</sup>	0.001	Ref.	0.89 (0.68-1.17)
Pvalue		0.04	0.91	0.09			0.39	0.87	0.03			0.42
<b>Haemorrhagic stroke</b>												
Person years	99,131	110,022	89,802	93,860		105,883	87,825	106,745	92,362		99,209	98,416
per 10 <sup>5</sup> person-years	57.5	58.2	60.1	94.8		57.6	53.5	65.6	93.1		83.7	64.0
No. of deaths	57	64	54	89		61	47	70	86		83	63
Model 1	Ref.	1.00 (0.71-1.44)	1.04 (0.72-1.52)	1.66 (1.19-2.31) <sup>b</sup>	0.003	Ref.	0.93 (0.63-1.36)	1.40 (0.81-1.61)	1.63 (1.17-2.26) <sup>b</sup>	0.004	Ref.	0.76 (0.55-1.05)

(HR; 95% CI)												
Pvalue		0.96	0.82	0.003			0.70	0.46	0.004			0.10
Model 2  (HR; 95% CI)	Ref.	0.96 (0.67- 1.37)	0.97 (0.66- 1.42)	1.43 (0.99- 2.05)	0.053	Ref.	0.84 (0.57- 1.23)	0.98 (0.67- 1.39)	1.23 (0.86- 1.75)	0.20	Ref.	0.91 (0.66- 1.27)
Pvalue		0.81	0.86	0.06			0.36	0.89	0.25			0.59
<b>Unclassified stroke</b>												
Person years	98,794	109,798	89,758	93,546		105,499	87,700	106,557	92,140		98,814	98,208
per 10 <sup>5</sup> person- years	24.3	39.2	43.4	58.8		18.9	39.9	48.8	58.6		41.5	36.6
No. of deaths	24	43	39	55		20	35	52	54		41	36
Model 1  (HR; 95% CI)	Ref.	1.60 (0.97- 2.64)	1.78 (1.07- 2.96) <sup>a</sup>	2.42 (1.50- 3.91) <sup>c</sup>	0.003	Ref.	2.09 (1.21- 3.63) <sup>b</sup>	2.56 (1.53- 4.29) <sup>c</sup>	3.09 (1.85- 5.17) <sup>c</sup>	<0.001	Ref.	0.88 (0.56- 1.37)
Pvalue		0.06	0.03	<0.001			0.008	< 0.001	< 0.001			0.57
Model 2  (HR; 95% CI)	Ref.	1.31 (0.79- 2.17)	1.33 (0.79- 2.24)	1.54 (0.93- 2.57)	0.42	Ref.	1.69 (0.97- 2.95)	1.86 (1.10- 3.14) <sup>a</sup>	1.80 (1.05- 3.07) <sup>a</sup>	0.12	Ref.	1.08 (0.69- 1.70)
Pvalue		0.29	0.28	0.09			0.06	0.02	0.03			0.72

Ref: reference; <sup>c</sup>  $P < 0.001$ , <sup>b</sup>  $P < 0.01$ , <sup>a</sup>  $P < 0.05$ ; model 1: a crude hazard ratio model without adjustment for confounders; model 2: a multivariate model adjusted for sex, age, diabetes, hypertension, dyslipidaemia, smoking, alcohol consumption, physical activity, body mass index, self-rated health, cancer, genitourinary disease (including nephropathy, prostatic disease, and gynaecologic diseases), chest disease (including chronic obstructive pulmonary disease, chronic bronchitis, emphysema, asthma, tuberculosis, and pneumonia) and platelet count.

**Table 3** Association of the PWRs and the PNRs with the risk of fatal stroke occurrence in the GBCS (n=27,796)

	Quartiles of the PWR				Quartiles of the PNR			
	the 1 <sup>st</sup> ( $\leq 30$ )	the 2 <sup>nd</sup> (30.01–36.11)	the 3 <sup>rd</sup> (36.12–43.38)	the 4 <sup>th</sup> ( $\geq 43.39$ )	the 1 <sup>st</sup> ( $\leq 48.64$ )	the 2 <sup>nd</sup> (48.65–61.11)	the 3 <sup>rd</sup> (61.12–76.25)	the 4 <sup>th</sup> ( $\geq 76.25$ )
<b>All stroke</b>								
Model 1 (HR, 95% CI)	1.00	0.71 (0.60–0.85), $P < 0.001$	0.61 (0.51–0.74), $P < 0.001$	0.46 (0.38–0.56), $P < 0.001$	1.00	0.64 (0.54–0.76), $P < 0.001$	0.56 (0.47–0.67), $P < 0.001$	0.38 (0.31–0.47), $P < 0.001$
Model 2 (HR, 95% CI)	1.00	0.89 (0.74–1.06), $P = 0.19$	0.89 (0.74–1.07), $P = 0.22$	0.85 (0.69–1.05), $P = 0.14$	1.00	0.82 (0.68–0.97), $P = 0.02$	0.84 (0.70–1.01), $P = 0.06$	0.76 (0.61–0.94), $P = 0.01$
P for trend			0.38				0.03	
<b>Ischaemic stroke</b>								
Model 1 (HR, 95% CI)	1.00	0.77 (0.61–1.00), $P = 0.04$	0.58 (0.44–0.75), $P < 0.001$	0.42 (0.31–0.56), $P < 0.001$	1.00	0.59 (0.46–0.75), $P < 0.001$	0.47 (0.36–0.61), $P < 0.001$	0.34 (0.26–0.47), $P < 0.001$
Model 2 (HR, 95% CI)	1.00	0.99 (0.77–1.26), $P = 0.93$	0.88 (0.67–1.15), $P = 0.35$	0.84 (0.62–1.14), $P = 0.26$	1.00	0.77 (0.60–0.98), $P = 0.04$	0.74 (0.57–0.97), $P = 0.03$	0.74 (0.55–1.01), $P = 0.05$
P for trend			0.60				0.06	
<b>Haemorrhagic stroke</b>								
Model 1 (HR, 95% CI)	1.00	0.57 (0.41–0.79), $P = 0.001$	0.60 (0.44–0.82), $P = 0.002$	0.43 (0.30–0.62), $P < 0.001$	1.00	0.62 (0.45–0.86), $P = 0.004$	0.65 (0.47–0.89), $P = 0.007$	0.40 (0.28–0.58), $P < 0.001$
Model 2 (HR, 95% CI)	1.00	0.69 (0.50–0.95), $P = 0.02$	0.80 (0.58–1.11), $P = 0.18$	0.72 (0.49–1.03), $P = 0.07$	1.00	0.76 (0.55–1.05), $P = 0.09$	0.91 (0.66–1.26), $P = 0.57$	0.71 (0.48–1.04), $P = 0.08$
P for trend			0.10				0.21	
<b>Unclassified stroke</b>								
Model 1 (HR, 95% CI)	1.00	0.80 (0.53–1.21), $P = 0.29$	0.73 (0.48–1.11), $P = 0.14$	0.61 (0.39–0.96), $P = 0.03$	1.00	0.83 (0.56–1.123), $P = 0.34$	0.65 (0.43–0.99), $P = 0.04$	0.44 (0.27–0.71), $P = 0.001$
Model 2 (HR, 95% CI)	1.00	1.01 (0.67–1.53), $P = 0.97$	1.07 (0.70–1.64), $P = 0.76$	1.17 (0.74–1.86), $P = 0.50$	1.00	1.05 (0.71–1.57), $P = 0.80$	0.99 (0.65–1.53), $P = 0.98$	0.89 (0.55–1.47), $P = 0.67$
P for trend			0.91				0.94	

PWR: platelet to white blood cell ratio; PNR: platelet to neutrophil ratio; model 1: a crude hazard ratio model without adjustment for confounders; model 2: a multivariate model adjusted for age, sex, diabetes, hypertension, dyslipidaemia, smoking, alcohol consumption, physical activity, body mass index, self-rated health, cancer, genitourinary disease (nephropathy, prostatic disease, and gynecologic diseases) and chest disease (COPD, chronic bronchitis, emphysema, asthma, tuberculosis, and pneumonia).

**Table 4** Association of the PWRs and the PNRs with the risk of fatal stroke among the participants without CVD at baseline and further hs-CRP adjustment (n=10,990)

	Quartiles of the PWR				Quartiles of the PNR			
	the 1 <sup>st</sup> (≤30)	the 2 <sup>nd</sup> (30.01–36.11)	the 3 <sup>rd</sup> (36.12–43.38)	the 4 <sup>th</sup> (≥43.39)	the 1 <sup>st</sup> (≤48.64)	the 2 <sup>nd</sup> (48.65–61.11)	the 3 <sup>rd</sup> (61.12–76.25)	the 4 <sup>th</sup> (≥76.25)
<b>All stroke</b>								
Model 1 (HR, 95% CI)	1.00	0.83 (0.66–1.06), <i>P</i> =0.13	0.74 (0.57–0.94), <i>P</i> =0.02	0.44 (0.32–0.60), <i>P</i> < 0.001	1.00	0.72(0.57–0.91), <i>P</i> =0.007	0.60 (0.47–0.78), <i>P</i> < 0.001	0.42 (0.31–0.57), <i>P</i> < 0.001
Model 3 (HR, 95% CI)	1.00	0.98 (0.77–1.25), <i>P</i> =0.88	0.97 (0.75–1.25), <i>P</i> =0.82	0.73 (0.53–1.00), <i>P</i> =0.05	1.00	0.86 (0.68–1.09), <i>P</i> =0.22	0.83 (0.64–1.08), <i>P</i> =0.18	0.74 (0.54–1.01), <i>P</i> =0.06
<i>P</i> for trend			0.23				0.23	
<b>Ischaemic stroke</b>								
Model 1 (HR, 95% CI)	1.00	0.92 (0.66–1.28), <i>P</i> =0.61	0.77 (0.54–1.10), <i>P</i> =0.15	0.38 (0.24–0.61), <i>P</i> < 0.001	1.00	0.69 (0.49–0.96), <i>P</i> =0.03	0.54 (0.37–0.78), <i>P</i> =0.001	0.38 (0.25–0.59), <i>P</i> < 0.001
Model 3 (HR, 95% CI)	1.00	1.09 (0.78–1.53), <i>P</i> =0.60	1.04 (0.72–1.49), <i>P</i> =0.83	0.66 (0.41–1.08), <i>P</i> =0.09	1.00	0.82 (0.59–1.15), <i>P</i> =0.25	0.76 (0.52–1.11), <i>P</i> =0.15	0.68 (0.43–1.07), <i>P</i> =0.09
<i>P</i> for trend			0.22				0.29	
<b>Haemorrhagic stroke</b>								
Model 1 (HR, 95% CI)	1.00	0.65 (0.42–1.02), <i>P</i> =0.06	0.72 (0.46–1.13), <i>P</i> =0.15	0.52 (0.31–0.87), <i>P</i> =0.01	1.00	0.65 (0.41–1.03), <i>P</i> =0.06	0.86 (0.56–1.33), <i>P</i> =0.50	0.52 (0.31–0.87), <i>P</i> =0.01
Model 3 (HR, 95% CI)	1.00	0.75 (0.48–1.18), <i>P</i> =0.21	0.91 (0.58–1.42), <i>P</i> =0.67	0.79 (0.46–1.34), <i>P</i> =0.38	1.00	0.77 (0.48–1.23), <i>P</i> =0.27	1.16 (0.74–1.81), <i>P</i> =0.52	0.85 (0.49–1.47), <i>P</i> =0.56
<i>P</i> for trend			0.61				0.37	
<b>Unclassified stroke</b>								
Model 1 (HR, 95% CI)	1.00	0.90 (0.54–1.52), <i>P</i> =0.71	0.66 (0.37–1.18), <i>P</i> =0.16	0.43 (0.22–0.87), <i>P</i> =0.02	1.00	0.88 (0.54–1.43), <i>P</i> =0.60	0.38 (0.19–0.73), <i>P</i> =0.004	0.38 (0.19–0.76), <i>P</i> =0.006
Model 3 (HR, 95% CI)	1.00	1.07 (0.64–1.82), <i>P</i> =0.79	0.90 (0.50–1.62), <i>P</i> =0.62	0.74 (0.36–1.51), <i>P</i> =0.41	1.00	1.07 (0.65–1.75), <i>P</i> =0.80	0.55 (0.28–1.08), <i>P</i> =0.08	0.71 (0.35–1.44), <i>P</i> =0.34
<i>P</i> for trend			0.76				0.21	

PWR: platelet to white blood cell ratio; PNR: platelet to neutrophil ratio; hs-CRP: high sensitivity C-reactive protein; CVD: relative cardiovascular diseases; model 1: a crude hazard ratio model without adjustment for confounders; model 3: a multivariate model adjusted for age, sex, diabetes, hypertension, dyslipidaemia, smoking, alcohol consumption, physical activity, body mass index, self-rated health, cancer, genitourinary disease (nephropathy, prostatic disease, and gynecologic diseases), chest disease (COPD, chronic bronchitis, emphysema, asthma, tuberculosis, and pneumonia) and hs-CRP.

**Table 5** Association of the PWR and the PNR changes with the risk of fatal stroke occurrence in the GBCS (n=11,038)

	Quartiles of the PWR change				Quartiles of the PNR change			
	the 1 <sup>st</sup> ( $\leq$ -0.11)	the 2 <sup>nd</sup> (-0.11-0.018)	the 3 <sup>rd</sup> (0.018-0.16)	the 4 <sup>th</sup> ( $\geq$ 0.16)	the 1 <sup>st</sup> ( $\leq$ -0.13)	the 2 <sup>nd</sup> (-0.13-0.03)	the 3 <sup>rd</sup> (0.03-0.21)	the 4 <sup>th</sup> ( $\geq$ 0.21)
<b>All stroke</b>								
Model 1 (HR, 95% CI)	1.00	0.74 (0.54-1.02), <i>P</i> =0.06	0.75 (0.55-1.03), <i>P</i> = 0.07	0.69 (0.50-0.95), <i>P</i> = 0.02	1.00	0.77 (0.57-1.05), <i>P</i> = 0.09	0.63 (0.46-0.88), <i>P</i> = 0.006	0.70 (0.51-0.96), <i>P</i> = 0.03
Model 2 (HR, 95% CI)	1.00	0.81 (0.59-1.00), <i>P</i> =0.18	0.85 (0.62-1.16), <i>P</i> =0.29	0.71 (0.51-0.98), <i>P</i> =0.03	1.00	0.86 (0.63-1.17), <i>P</i> =0.34	0.69 (0.50-0.96), <i>P</i> =0.03	0.73 (0.54-1.01), <i>P</i> =0.05
<i>P</i> for trend		0.19				0.10		
<b>Ischaemic stroke</b>								
Model 1 (HR, 95% CI)	1.00	0.75 (0.48-1.16), <i>P</i> =0.19	0.72 (0.46-1.12), <i>P</i> = 0.14	0.76 (0.49-1.18), <i>P</i> = 0.23	1.00	0.67 (0.43-1.06), <i>P</i> = 0.08	0.68 (0.44-1.07), <i>P</i> = 0.09	0.82 (0.54-1.25), <i>P</i> = 0.36
Model 2 (HR, 95% CI)	1.00	0.79 (0.51-1.23), <i>P</i> =0.30	0.81 (0.52-1.26), <i>P</i> =0.34	0.78 (0.50-1.20), <i>P</i> =0.26	1.00	0.74 (0.47-1.17), <i>P</i> =0.20	0.74 (0.47-1.16), <i>P</i> =0.19	0.85 (0.56-1.31), <i>P</i> =0.47
<i>P</i> for trend		0.63				0.50		
<b>Haemorrhagic stroke</b>								
Model 1 (HR, 95% CI)	1.00	0.66 (0.35-1.21), <i>P</i> =0.17	0.89 (0.51-1.55), <i>P</i> =0.67	0.51 (0.26-0.99), <i>P</i> = 0.04	1.00	0.65 (0.36-1.16), <i>P</i> =0.15	0.61 (0.34-1.10), <i>P</i> =0.10	0.44 (0.23-0.85), <i>P</i> = 0.01
Model 2 (HR, 95% CI)	1.00	0.71 (0.38-1.31), <i>P</i> =0.27	0.97 (0.55-1.72), <i>P</i> =0.93	0.48 (0.25-0.95), <i>P</i> =0.03	1.00	0.72 (0.40-1.28), <i>P</i> =0.26	0.64 (0.36-1.16), <i>P</i> =0.14	0.44 (0.23-0.85), <i>P</i> =0.01
<i>P</i> for trend		0.13				0.09		
<b>Unclassified stroke</b>								
Model 1 (HR, 95% CI)	1.00	0.85 (0.44-1.65), <i>P</i> =0.63	0.63 (0.31-1.31), <i>P</i> =0.22	0.75 (0.37-1.49), <i>P</i> = 0.41	1.00	1.23 (0.65-2.32), <i>P</i> =0.53	0.52 (0.23-1.17), <i>P</i> =0.11	0.80 (0.39-1.63), <i>P</i> = 0.55
Model 2 (HR, 95% CI)	1.00	0.94 (0.48-1.84), <i>P</i> =0.86	0.72 (0.35-1.49), <i>P</i> =0.38	0.77 (0.38-1.55), <i>P</i> =0.50	1.00	1.36 (0.71-2.60), <i>P</i> =0.35	0.57 (0.25-1.29), <i>P</i> =0.18	0.84 (0.41-1.73), <i>P</i> =0.64
<i>P</i> for trend		0.79				0.16		

PWR: platelet-to -white blood cell ratio; PNR: platelet-to-neutrophil ratio; hs-CRP: high-sensitivity C-reactive protein; model 1: a crude hazard ratio model without adjustments; model 3: a multivariate model adjusted for age, sex, diabetes, hypertension, dyslipidaemia, smoking, alcohol consumption, physical activity, body mass index, self-rated health, cancer, genitourinary disease(nephropathy, prostatic disease, and gynecologic diseases) and chest disease(COPD, chronic bronchitis, emphysema, asthma, tuberculosis, and pneumonia) and hs-CRP.

## Figures




Figure 1

Flow diagram of participants selected for the analysis of this study





Figure 2

Association between the risk of fatal stroke and the platelet-to-white blood cell ratio and the platelet-to-neutrophil ratio with the restricted cubic spline curves model in the Guangzhou Biobank Cohort Study followed up for a mean 14.3 years. The solid blue line is the multivariable adjusted hazard ratio, with dashed lines showing 95% confidence intervals with three knots. A multivariate model was used, adjusted for sex, age, diabetes, hypertension, dyslipidaemia, smoking, alcohol consumption, physical activity, body mass index, self-rated health, cancer, genitourinary diseases, chest disease and platelet count.



**Figure 3**

Association between the WBC, the NEUT, and the PLT quartiles and the risk of fatal stroke in participants of the GBCS.

A, B, C plot an adjusted hazard ratio and 95% confidence interval for the WBC, NEUT, PLT quartiles with the P value for trend. The adjusted confounders include age, sex, hypertension, diabetes, dyslipidaemia, smoking, alcohol drinking, physical activity, body mass index, self-rated health, cancer, genitourinary disease and chest disease.

**Figure 4**

Association between the PWRs, the PNRs and the risk of fatal stroke occurrence in the GBCS

A, B plot an adjusted hazard ratio and 95% confidence interval for the PWR, PNR quartiles with the P value for trend. The adjusted confounders include age, sex, hypertension, diabetes, dyslipidaemia, smoking, alcohol drinking, physical activity, body mass index, self-rated health, cancer, genitourinary disease and chest disease.

**Figure 5**

Association between the PWRs, the PNRs and the risk of fatal stroke among the participants without cardiovascular diseases at baseline

A, B plot an adjusted hazard ratio and 95% confidence interval for the PWR, PNR quartiles with the P value for trend. The adjusted confounders include age, sex, diabetes, hypertension, dyslipidaemia, smoking, alcohol consumption, physical activity, body mass index, self-rated health, cancer, genitourinary disease (nephropathy, prostatic disease, and gynecologic diseases), chest disease (COPD, chronic bronchitis, emphysema, asthma, tuberculosis, and pneumonia) and hs-CRP.

**Figure 6**

Association between the PWRs, the PNRs and fatal stroke among the participants in the first follow-up. This figure plots an adjusted hazard ratio and 95% confidence interval for PWR and PNR change alongside with the P value for trend. The adjusted confounders include age, sex, diabetes, hypertension, dyslipidaemia, smoking, alcohol consumption, physical activity, body mass index, self-rated health, cancer, and genitourinary disease(nephropathy, prostatic disease, and gynecologic diseases) , chest disease(COPD, chronic bronchitis, emphysema, asthma, tuberculosis, pneumonia) and hs-CRP.

## Figure 7

Association between the PWR and the PNR changes (-20% to 20%) and fatal stroke among the participants in the first follow-up. This figure plots an adjusted hazard ratio and 95% confidence interval PWR and PNR change alongside with the P value for trend. The adjusted confounders include age, sex, diabetes, hypertension, dyslipidaemia, smoking, alcohol consumption, physical activity, body mass index, self-rated health, cancer, and genitourinary disease(nephropathy, prostatic disease, and gynecologic diseases) , chest disease(COPD, chronic bronchitis, emphysema, asthma, tuberculosis, pneumonia) and hs-CRP.

## Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [supplementarytables202204.docx](#)